Brief: Oncolytics Biotech® Announces Type C FDA Meeting To Discuss Single-Arm Registrational Pathway For Pelareorep In Anal Cancer
April 6 (Reuters) - Oncolytics Biotech Inc ONCY.O: ONCOLYTICS BIOTECH® ANNOUNCES TYPE C FDA MEETING TO DISCUSS SINGLE-ARM REGISTRATIONAL PATHWAY FOR PELAREOREP IN ANAL CANCER ONCOLYTICS BIOTECH INC - SCHEDULES TYPE C FDA MEETING ON APRIL 16, 2026 FOR PELAREOREP IN ANAL CANCER ONCOLYTICS BIOTECH INC - MEETING TO DISCUSS SINGLE-ARM PIVOTAL STUDY OF PELAREOREP IN SECOND-LINE AND LATER SCAC Source text: ID:nGNX36LGrp Further company coverage: ONCY.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oncolytics Biotech
See all newsBrief: Oncolytics Biotech Announces Clinical Supply Agreement To Evaluate Pelareorep In Combination With Loqtorzi In Squamous Cell Anal Carcinoma
Brief: Oncolytics Says Pelareorep Shows Durable Survival Benefit in Anal Cancer
Brief: Oncolytics Biotech Expects Final Cohort 4 Results Of Goblet Study In Q4 2026
Brief: Oncolytics Biotech® Secures Patent Protection To Late 2040S And Provides Intellectual Property Portfolio Update
Brief: Oncolytics Biotech® Aligns With FDA On Registrational Path For Second-Line Ras-Mutant Mss Colorectal Cancer